The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Thomas Müller

St. Joseph Hospital Berlin-Weissensee

Department of Neurology

Berlin

Germany

[email]@ruhr-uni-bochum.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • St. Joseph Hospital Berlin-Weissensee, Department of Neurology, Berlin, Germany. 1999 - 2010

References

  1. Entacapone. Müller, T. Expert. Opin. Drug. Metab. Toxicol (2010) [Pubmed]
  2. Role of intraspinal steroid application in patients with multiple sclerosis. Müller, T. Expert. Rev. Neurother (2009) [Pubmed]
  3. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. Müller, T., Kolf, K., Ander, L., Woitalla, D., Muhlack, S. Clin. Neuropharmacol (2008) [Pubmed]
  4. Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells. Müller, T., Przuntek, H., Rieks, M., Mackowiak, A. Neurol. Res. (2008) [Pubmed]
  5. Role of homocysteine in the treatment of Parkinson's disease. Müller, T. Expert. Rev. Neurother (2008) [Pubmed]
  6. Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease. Müller, T., Woitalla, D., Goetze, O., Erdmann, C. Mov. Disord. (2008) [Pubmed]
  7. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. Müller, T., Ander, L., Kolf, K., Woitalla, D., Muhlack, S. J. Neural. Transm (2007) [Pubmed]
  8. Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease. Müller, T., Muhlack, S. Clin. Neuropharmacol (2007) [Pubmed]
  9. Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease. Müller, T., Welnic, J., Woitalla, D., Muhlack, S. Neurosci. Lett. (2007) [Pubmed]
  10. Rivastigmine in the treatment of patients with Alzheimer's disease. Müller, T. Neuropsychiatr. Dis. Treat (2007) [Pubmed]
  11. Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease. Müller, T., Woitalla, D., Russ, H., Hock, K., Haeger, D.A. J. Neural. Transm (2007) [Pubmed]
  12. Acute levodopa administration reduces cortisol release in patients with Parkinson's disease. Müller, T., Welnic, J., Muhlack, S. J. Neural. Transm (2007) [Pubmed]
  13. Entacapone improves complex movement performance in patients with Parkinson's disease. Müller, T., Erdmann, C., Muhlack, S., Bremen, D., Przuntek, H., Woitalla, D. J. Clin. Neurosci (2007) [Pubmed]
  14. The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. Müller, T., Welnic, J., Fuchs, G., Baas, H., Ebersbach, G., Reichmann, H. J. Neural Transm. Suppl. (2006) [Pubmed]
  15. Diagnostic aspects of early Parkinson's disease. Müller, T., Fuchs, G., Hahne, M., Klein, W., Schwarz, M. J. Neurol. (2006) [Pubmed]
  16. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Müller, T., Erdmann, C., Muhlack, S., Bremen, D., Przuntek, H., Woitalla, D. Mov. Disord. (2006) [Pubmed]
  17. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. Müller, T., Erdmann, C., Muhlack, S., Bremen, D., Przuntek, H., Goetze, O., Woitalla, D. J. Neural. Transm (2006) [Pubmed]
  18. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Müller, T., Erdmann, C., Bremen, D., Schmidt, W.E., Muhlack, S., Woitalla, D., Goetze, O. Clin. Neuropharmacol (2006) [Pubmed]
  19. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Müller, T., Kuhn, W. Eur. J. Clin. Pharmacol. (2006) [Pubmed]
  20. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Müller, T., Russ, H. Expert. Opin. Pharmacother (2006) [Pubmed]
  21. Efficacy of budipine and placebo in untreated patients with Parkinson's disease. Müller, T., Kuhn, W., Przuntek, H. J. Neural. Transm (2005) [Pubmed]
  22. Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease. Müller, T., Lang, U.E., Muhlack, S., Welnic, J., Hellweg, R. Clin. Neuropharmacol (2005) [Pubmed]
  23. Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson disease. Müller, T., Fowler, B., Kuhn, W. Clin. Neuropharmacol (2005) [Pubmed]
  24. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. Müller, T., Voss, B., Hellwig, K., Josef Stein, F., Schulte, T., Przuntek, H. CNS. Drugs (2004) [Pubmed]
  25. Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment. Müller, T., Benz, S., Börnke, C., Przuntek, H. Acta Neurol. Scand. (2004) [Pubmed]
  26. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Müller, T., Renger, K., Kuhn, W. Arch. Neurol. (2004) [Pubmed]
  27. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Müller, T., Mannel, M., Murck, H., Rahlfs, V.W. Psychosom. Med (2004) [Pubmed]
  28. Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson's disease. Müller, T., Benz, S., Börnke, C., Muhlack, S., Woitalla, D., Przuntek, H. J. Neural Transm. Suppl. (2004) [Pubmed]
  29. Antiapoptotic effects of budipine. Müller, T., Przuntek, H., Krüger, R., Mackowiak, A. J. Neural. Transm (2004) [Pubmed]
  30. Is levodopa toxic?. Müller, T., Hefter, H., Hueber, R., Jost, W.H., Leenders, K.L., Odin, P., Schwarz, J. J. Neurol. (2004) [Pubmed]
  31. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. Müller, T., Kuhn, W., Schulte, T., Przuntek, H. Neurosci. Lett. (2003) [Pubmed]
  32. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Müller, T., Büttner, T., Gholipour, A.F., Kuhn, W. Neurosci. Lett. (2003) [Pubmed]
  33. Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease. Müller, T., Benz, S., Börnke, C., Russ, H., Przuntek, H. J. Neural. Transm (2003) [Pubmed]
  34. Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients. Müller, T., Meisel, M., Russ, H., Przuntek, H. J. Neurol. Sci. (2003) [Pubmed]
  35. Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics. Müller, T., Voss, B., Hellwig, K., Przuntek, H. NeuroRehabilitation (2003) [Pubmed]
  36. Drug treatment of non-motor symptoms in Parkinson's disease. Müller, T. Expert. Opin. Pharmacother (2002) [Pubmed]
  37. Progress of visual dysfunction in Parkinson's disease. Müller, T., Woitalla, D., Peters, S., Kohla, K., Przuntek, H. Acta Neurol. Scand. (2002) [Pubmed]
  38. Quantification of the dopaminergic response in Parkinson's disease. Müller, T., Benz, S. Parkinsonism Relat. Disord. (2002) [Pubmed]
  39. 3-OMD and homocysteine plasma levels in parkinsonian patients. Müller, T., Woitalla, D., Fowler, B., Kuhn, W. J. Neural. Transm (2002) [Pubmed]
  40. Dopaminergic substitution in Parkinson's disease. Müller, T. Expert. Opin. Pharmacother (2002) [Pubmed]
  41. CPI-1189. Centaur. Müller, T. Curr. Opin. Investig. Drugs (2002) [Pubmed]
  42. Apomorphine delays simple reaction time in Parkinsonian patients. Müller, T., Benz, S., Przuntek, H. Parkinsonism Relat. Disord. (2002) [Pubmed]
  43. Non-dopaminergic drug treatment of Parkinson's disease. Müller, T. Expert. Opin. Pharmacother (2001) [Pubmed]
  44. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Müller, T., Woitalla, D., Hauptmann, B., Fowler, B., Kuhn, W. Neurosci. Lett. (2001) [Pubmed]
  45. Delay of simple reaction time after levodopa intake. Müller, T., Benz, S., Börnke, C. Clin. Neurophysiol (2001) [Pubmed]
  46. Tolcapone increases maximum concentration of levodopa. Müller, T., Woitalla, D., Schulz, D., Peters, S., Kuhn, W., Przuntek, H. J. Neural. Transm (2000) [Pubmed]
  47. R- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patients. Müller, T., Sällström Baum, S., Häussermann, P., Przuntek, H., Rommelspacher, H., Kuhn, W. J. Neurol. Sci. (1999) [Pubmed]
  48. Iron deposits in the subthalamic nuclei in Hallervorden-Spatz disease. Müller, T., Amoiridis, G., Kuhn, W., Przuntek, H. Eur. Neurol. (1999) [Pubmed]
 
WikiGenes - Universities